Announcement
Thank you for attending THSNA 2026. The virtual meeting is now closed.
Thank you for attending THSNA 2026. The virtual meeting is now closed.
Presentation Details
| Clotting Potential of a Novel Mesoporous Bioactive Glass Absorbable and Antimicrobial Hemostatic Agent Keith A.Moskowitz1, 2, Scott Janis2, Emily Alhassan2, John Waldo3, Mark Towler3, Pedro Abrantes4, Vanessa Jooste4, Brett Janis2. 1KA Bioscience Consultants, LLC, Westfield, IN, USA.2DesiCorp Inc., Louisville, KY, USA.3Missouri University of Science & Technology, Rolla, MO, USA.4University of the Western Cape, Cape Town, South Africa |
Abstract
Background: Advances in topical or implantable hemostatic agents have advanced significantly since the Gulf and Afghan wars. Yet, several challenges remain in terms of long-term absorption and degradation and the risk of severe chronic infection. Novel microporous bioactive glasses (MBGs) containing tantalum (Ta-MBGs) have absorbable and degradable in vivo properties and showed hemostatic promise in preliminary murine tail-bleeding assays. Objectives: Here, we sought to analyze the clotting potential of MBG and Ta-MBG hemostats in vitro relative to commonly used battlefield/surgical agents and to assess MBG and Ta-MBG antimicrobial activity. Methods: Ta-MBG and MBG were prepared by proprietary methods at the Missouri University of Science and Technology (MS&T). Clotting kinetics were performed using a microtiter plate based clotting assay. Citrated-human plasma, alone or in the presence of varying doses of hemostatic agents Ta-MBG, MBG, CeloxTM, Kaolin (QuickClot® Combat Gauze® active ingredient) or plain glass beads were incubated in plasma for ~ 15 minutes at ambient temperature then quickly centrifuged. 200 µl was added in quintuplet to individual wells of a 96 well plate containing 21 µl of 0.1 M CaCl2 (10mM final) and the A 380 nm recorded for 45 minutes at 37°C. 380 nm was chosen to minimize potential sample hemolysis effects absorption which peaks at 415 nm. In some cases, MBG clotting was performed in the presence of low-dose (0.1 U/ml) or hi-dose (1U/ml) unfractionated heparin. Lag Time, Vmax, Time to Vmax, and total clot density (OD max- OD min) were analyzed from the A 380 vs time curves. Antimicrobial activity of MBG was assessed using broth microdilution assays against gram -positive bacteria S. aureus; gram -negative bacteria P. aeruginosa; and fungi C. albicans and C. glabrata. Results: MBG and Ta-MBG depicted dose dependent decreases in lag -time and time to Vmax with increasing concentration of hemostat while the Vmax generally remained constant. When all hemostats were compared at 0.5 mg/ml, the Kaolin control clotted fastest having a lag time of 417+/- 35 s, followed by Ta-MBG (560 +/- 53 s) then MBG (765 +/- 57 s). Notably, plasma only, Celox and plain glass beads did not clot (Figure 1). Clot density coincided with lag time. Ta-MBG also clotted in the presence of 0.1, but not 1.0 U/ml heparin, albeit at a lesser rate. Only Ta-MBG displayed robust antimicrobial activity against S. aureus and P. aeruginosa, while also demonstrating antifungal activity for an extended period. Conclusions: Ta-MBG represents a novel procoagulant hemostat depicting clot acceleration, antimicrobial activity and is both absorbable and degradable (not shown). Additional coagulopathic large animal pre-clinical studies are necessary to ascertain Ta-MBG in vivo efficacy.
No part of this publication may be reproduced, distributed, or transmitted in any form or by any means, including photocopying, recording, or other electronic or mechanical methods, without the prior written permission of the author.
No part of this publication may be reproduced, distributed, or transmitted in any form or by any means, including photocopying, recording, or other electronic or mechanical methods, without the prior written permission of the author.